Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 3:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 340 matching trials from the live ClinicalTrials.gov search.
Conditions
Myeloablative Conditioning, HLA-mismatched Bone Marrow Transplantation, Graft Survival, Transplantation, Bone Marrow
Interventions
Cyclophosphamide, TBI, Busulfan, Unmanipulated Bone Marrow, Tacrolimus, Mycophenolate mofetil
Drug · Radiation · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
6 Months to 25 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
7
States / cities
Aurora, Colorado • Wilmington, Delaware • St. Petersburg, Florida + 4 more
Withdrawn Not applicable Interventional

Taking POSNA's OrthoKids to the People

NCT04996745
Conditions
Fracture Forearm, Pediatric ALL
Interventions
Tablet-based educational intervention
Behavioral
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
0 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Orleans, Louisiana
Conditions
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Cytarabine, Flotetuzumab
Drug · Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 20 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 16 more
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Interventions
Daratumumab, Vincristine, Prednisone, Doxorubicin, Peg-asparaginase, Cyclophosphamide, Cytarabine, 6-mercaptopurine, Methotrexate
Drug · Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
1 Year to 30 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Oakland, California + 22 more
Conditions
Acute Lung Injury
Interventions
Calfactant, Air placebo
Drug · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Months to 21 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 12 more
Conditions
Central Nervous System Neoplasm, Infantile Fibrosarcoma, Recurrent Acute Leukemia, Refractory Acute Leukemia, Solid Neoplasm
Interventions
Larotrectinib Sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
78
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 67 more
Conditions
Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Acute Leukemias
Interventions
EPZ-5676
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
3 Months to 18 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 5 more
Conditions
Acute Lymphoblastic Leukemia
Interventions
huCART19
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
3 Months to 29 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Asthma, Pediatric ALL
Interventions
budesonide, beclomethasone
Drug
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
Up to 18 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Brooklyn, New York
Conditions
Cancer, Pediatric Cancer, Chemotherapy Effect, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Pediatric, Hematopoietic Stem Cell Transplantation (HSCT)
Interventions
Massage therapy, Standard of care
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
12 Years to 21 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Philadelphia, Pennsylvania
Conditions
Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasia
Interventions
SAR443579
Drug
Lead sponsor
Sanofi
Industry
Eligibility
1 Year and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
10
States / cities
Duarte, California • Atlanta, Georgia • Boston, Massachusetts + 7 more
Conditions
Extracorporeal Membrane Oxygenation Complication, Pediatric ALL, Anticoagulants
Interventions
Bivalirudin, Unfractionated heparin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
1 Day to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Promyelocytic Leukemia (M3), Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia
Interventions
bortezomib, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Arcadia, California
Conditions
Acute Lymphoblastic Leukemia
Interventions
prednisone, doxorubicin, vincristine, methotrexate, asparaginase, dexamethasone, cranial radiation, leucovorin, cytarabine, hydrocortisone, 6-mercaptopurine (6-MP), e. coli L-asparaginase
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Conditions
Acute Lymphoblastic Leukemia, Pediatric, Pediatric ALL, Pediatric Lymphoma, Bone Loss, Metabolic Syndrome, Habitual Physical Activity, Precursor Cell Lymphoblastic Leukemia, Lymphoma, Leukemia, Lymphoid Leukemia, Pediatric, Osteoporosis, Osteoporosis Risk
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
5 Years to 18 Years
Enrollment
40 participants
Timeline
2020 – 2024
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Ewing Sarcoma, Osteosarcoma, Neuroblastoma, Acute Lymphoblastic Leukemia, Neurofibromatosis Type 1
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 35 Years
Enrollment
1,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Enrolling by invitation No phase listed Observational

Biology Studies of Hematologic Cancers

NCT00923442
Conditions
Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome (MDS), Non-Hodgkins Lymphoma, Acute Myelogenous Leukemia, Hodgkins Lymphoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 120 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Not applicable Interventional Accepts healthy volunteers

Prehospital Provider Training With Augmented Reality (AR)

NCT05686590
Conditions
Hypoglycemia, Pediatric ALL
Interventions
Augmented Reality Headset
Behavioral
Lead sponsor
Thomas Caruso
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Mountain View, California • Palo Alto, California
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Luveltamab tazevibulin
Drug
Lead sponsor
Sutro Biopharma, Inc.
Industry
Eligibility
1 Day to 12 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 19 more
Conditions
Fatigue, Leukemia, Long-term Effects Secondary to Cancer Therapy in Children
Interventions
laboratory biomarker analysis, metabolic assessment, questionnaire administration, assessment of therapy complications, fatigue assessment and management, quality-of-life assessment
Other · Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
1 Year to 20 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
3
States / cities
Nashville, Tennessee
Completed No phase listed Observational Accepts healthy volunteers

Assessing Neurophysiological and Cognitive Function in School Children

NCT06209528
Conditions
Pediatric ALL
Interventions
Not listed
Lead sponsor
Life University
Other
Eligibility
5 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Chippewa Falls, Wisconsin
Conditions
Relapsed Pediatric ALL, Hematopoietic Cell Transplantation, Hematologic Malignancy
Interventions
Anti-Thymocyte Globulin (Rabbit), Cyclophosphamide, Fludarabine, Thiotepa, Mesna, Melphalan, Filgrastim, CliniMACS System
Drug · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies
Interventions
laboratory biomarker analysis, quizartinib, sorafenib tosylate
Other · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Monrovia, California
Conditions
Pediatric ALL
Interventions
orotracheal intubation
Device
Lead sponsor
Verathon
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Timeline
2016 – 2020
U.S. locations
1
States / cities
Dallas, Texas